MCRB - Seres Therapeutics' Balancing Act: Breakthrough IP And Financing Concerns
2024-01-30 05:15:11 ET
Summary
- Seres Therapeutics focuses on microbiome therapies, with its leading product VOWST preventing recurrent Clostridioides difficile infection.
- The company is developing SER-155, which has FDA Fast Track Designation, and has other products in its pipeline for ulcerative colitis and oncology applications.
- Despite promising research, due to the company's financing concerns and heavy short interest, I rate it a "sell" for now.
- Still, I discourage shorting the shares as many potential unforeseen catalysts could squeeze the shares higher. I think shorting at this point is too risky.
...
Seres Therapeutics' Balancing Act: Breakthrough IP And Financing Concerns